Literature DB >> 26105145

Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients.

Alicja Bartkowska-Śniatkowska1, Agnieszka Bienert2, Paweł Wiczling3, Jowita Rosada-Kurasińska1, Marzena Zielińska4, Justyna Warzybok2, Agnieszka Borsuk3, Dick Tibboel5, Roman Kaliszan3, Edmund Grześkowiak2.   

Abstract

The aim of this study was to develop a population pharmacokinetic model of sufentanil and to assess the influence of covariates in critically ill children admitted to a pediatric intensive care unit. After institutional approval, 41 children were enrolled in the study. Blood samples for pharmacokinetic (PK) assessment were collected from routinely placed arterial catheters during and after discontinuation of infusion. Population nonlinear mixed-effects modeling was performed using NONMEM. A 2-compartment model described sufentanil PK sufficiently. Typical values of the central and peripheral volume of distribution and the metabolic and intercompartmental clearance for a theoretical patient weighing 70 kg were VC = 7.90 l, VT  = 481 L, Cl =  5.3 L/h, and Q = 38.3 L/h, respectively. High interindividual variability of all PK parameters was noted. Allometric/isometric principles to scale sufentanil PK revealed that to achieve the same steady-state sufentanil concentrations in plasma for pediatric patients of different body weights, the infusion rate should follow the formula (infusion rate for a 70-kg adult patient, μg/h) × (body weight/70 kg)(0.75). Severity of illness described by PRISM score, the monitored physiological and laboratory parameters, and coadministered drugs such as vasopressors were not found to be significant covariates.
© 2015, The American College of Clinical Pharmacology.

Entities:  

Keywords:  critical ill children; population PK; sedation; sufentanil

Mesh:

Substances:

Year:  2015        PMID: 26105145     DOI: 10.1002/jcph.577

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

1.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 2.  Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

3.  The optimal bolus dose of sufentanil for satisfactory laryngeal mask airway (LMA) insertion conditions in chinese pediatric patients: A prospective double-blind randomized controlled trial (CONSORT).

Authors:  Na Li; Yong Chen; Bishan Ouyang; Guige Li; Guanwen Lin; Yan Li; Tiejun Li
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

4.  The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients. A Bayesian approach with informative priors.

Authors:  Paweł Wiczling; Alicja Bartkowska-Śniatkowska; Oliwia Szerkus; Danuta Siluk; Jowita Rosada-Kurasińska; Justyna Warzybok; Agnieszka Borsuk; Roman Kaliszan; Edmund Grześkowiak; Agnieszka Bienert
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-05-24       Impact factor: 2.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.